Form 4: Pliant Therapeutics CFO Keith Cummings Acquires Shares Following Performance Milestone

Keith Lamont Cummings, CFO of Pliant Therapeutics, acquired 21,313 shares of common stock on July 9, 2024, following the achievement of a performance milestone related to the company's total shareholder return.

Summary

• On July 9, 2024, Keith Lamont Cummings, the Chief Financial Officer of Pliant Therapeutics, acquired 21,313 shares of common stock.
• This acquisition resulted from the vesting of performance-vested stock units granted on July 28, 2022.
• The vesting was contingent upon the achievement of pre-established performance criteria.
• The Compensation Committee of Pliant Therapeutics' Board of Directors certified that the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index had been met.
• Following the transaction, Cummings directly owns 293,026 shares of Pliant Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of shares indicates the achievement of performance goals, which is generally a positive sign. The CFO increasing their stake in the company is also a positive indicator.

Positives

• The vesting of performance-based stock units suggests that Pliant Therapeutics achieved a significant performance milestone related to shareholder return.
• The CFO's increased stake in the company could signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The vesting of performance-based stock units is a common incentive mechanism used to align management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the vesting of performance-based stock units as a positive sign, indicating that the company is meeting its performance goals.
• Employees may be motivated by the company's achievement of performance milestones.

Key Dates